In recent trading session, Gilead Sciences, Inc (NASDAQ:GILD) saw 4.45 million shares changing hands at last check today with its beta currently measuring 0.29. Company’s recent per share price level of $102.83 trading at -$3.32 or -3.12% at last check today assigns it a market valuation of $128.20B. That most recent trading price of GILD’s stock is at a discount of -16.66% from its 52-week high price of $119.96 and is indicating a premium of 39.64% from its 52-week low price of $62.07. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.45 million shares which gives us an average trading volume of 9.43 million if we extend that period to 3-months.
For Gilead Sciences, Inc (GILD), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.83. Splitting up the data highlights that, out of 17 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 6 suggested the stock as a Hold whereas 11 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 1.96 in the current quarter.
Gilead Sciences, Inc (NASDAQ:GILD) trade information
Upright in the red during last session for losing -3.12%, in the last five days GILD remained trading in the red while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $102.83 price level, adding 4.4% to its value on the day. Gilead Sciences, Inc’s shares saw a change of 11.33% in year-to-date performance and have moved -1.63% in past 5-day. Gilead Sciences, Inc (NASDAQ:GILD) showed a performance of -5.89% in past 30-days. Number of shares sold short was 21.39 million shares which calculate 2.0 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 125.5 to the stock, which implies a rise of 18.06% to its recent value today. Analysts have been projecting 83 as a low price target for the stock while placing it at a high target of 132. It follows that stock’s current price would jump 19.28% in reaching the projected high whereas dropping to the targeted low would mean a gain of 19.28% for stock’s current value.
Gilead Sciences, Inc (GILD) estimates and forecasts
This year revenue growth is estimated to fall -0.34% from the last financial year’s standing.
16 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.96B for the same. And 15 analysts are in estimates of company making revenue of 7.38B in the next quarter. Company posted 6.95B and 7.54B of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -38.13% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 72.43% while estimates for its earnings growth in next 5 years are of 25.55%.
GILD Dividends
Gilead Sciences, Inc is more likely to be releasing its next quarterly report on 2025-Apr-23 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 3.01%, the share has a forward dividend of 3.10 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 3.97%.
Gilead Sciences, Inc (NASDAQ:GILD)’s Major holders
Insiders are in possession of 0.12% of company’s total shares while institution are holding 89.51 percent of that, with stock having share float percentage of 89.61%. Investors also watch the number of corporate investors in a company very closely, which is 89.51% institutions for Gilead Sciences, Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at GILD for having 120.63 million shares of worth $8.28 billion. And as of 2024-06-30, it was holding 9.6738 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 115.26 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.2431 of outstanding shares, having a total worth of $7.91 billion.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 39.06 shares of worth $4.0 billion or 3.14% of the total outstanding shares. The later fund manager was in possession of 33.73 shares on Dec 31, 2024 , making its stake of worth around $3.46 billion in the company or a holder of 2.71% of company’s stock.
